BBA
ATRA icon

Baker Bros. Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Baker Bros. Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,767
Closed -$2.16M – 108
2023
Q1 		$2.16M Hold
29,767
– – 0.01% 89
2022
Q4 		$2.44M Hold
29,767
– – 0.01% 93
2022
Q3 		$2.81M Hold
29,767
– – 0.02% 94
2022
Q2 		$5.8M Buy
+29,767
New +$4.86M 0.03% 77

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baker Bros. Advisors's ATRA Position: Q2 2023 in Review

Baker Bros. Advisors sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 29,767 shares — an estimated $2.16M sold.

Baker Bros. Advisors first reported a position in ATRA in Q2 2022 and held it in 4 quarters. The position peaked at $5.8M in Q2 2022. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

  • Baker Bros. Advisors reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 29,767 Atara Biotherapeutics shares in Q2 2023, an estimated $2.16M.
  • Baker Bros. Advisors first reported a position in Atara Biotherapeutics in Q2 2022 and held it in 4 quarters.
  • Baker Bros. Advisors's Atara Biotherapeutics position peaked at $5.8M in Q2 2022.
  • 118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.